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Material/methods: Dosimeters (1 x 1 x 4.5 cm3) of varying 
chemical compositions were produced. They contained leuco-
malachite green (LMG) dye as the active component, 
chloroform and silicone elastomer.  
Twelve different batches were irradiated with 60 MeV proton 
beams, using a 40 mm circular collimator, to different doses 
(0 – 30 Gy). Irradiations were performed with both a low and 
a high dose rate (0.23 and 0.55 Gy/s). For comparison, 
depth–dose distributions were measured in water with a 
Markus-type, plane-parallel ionization chamber. 
Simultaneously, dosimeters from the same batches were 
irradiated with 6 MV photon beams in a 10 cm square field on 
a linear accelerator. 
All dosimeters were read out before irradiation and four 
hours after, at a wavelength of 635 nm. The read-out was 
performed with a home-built 1D-scanner with a depth 
resolution of 0.2 mm for the proton irradiated dosimeters, 
while a spectrophotometer was used for the photon read-out. 
The dose-rate dependency was compared for proton and 
photon irradiations. The ratio of Bragg-peak to plateau 
response (at 1 cm) was compared between batches. 
Results: The effect of lowering the dose rate was similar for 
proton and photon beams, although the beam qualities were 
different. The dose response was higher at a low dose rate, 
but at increasing dye concentration the effect was reduced. 
Significant under-response was observed in the Bragg peak. 
The peak-to-plateau ratio was improved from (2.5 ± 0.1) to 
(3.0 ± 0.04) by increasing the dye concentration from 0.1 to 
0.3 % (w/w). By increasing the curing-agent concentration 
from 5 to 9 % (w/w), the ratio further improved to (3.7 ± 0.4) 
and (3.5 ± 0.1) for the same respective dye concentrations.  
Conclusion: The 3D radiochromic silicone based dosimeter 
has for the first time been investigated in proton beams, and 
it was demonstrated that chemical modifications could 
influence the dosimeter response. 
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Purpose: There is interest in the particle therapy community 
to use prompt gammas (PG), a natural byproduct of particle 
treatment, for range verification and eventually dose control 
(Knopf et al. 2015). However, PG production is a rare process 
and therefore estimating PGs exiting a patient during a 
proton treatment plan executed by a Monte-Carlo simulation 
converges slowly. Recently, different approaches to 
accelerating the estimation of PG yield have been presented. 
Sterpin et al. (2015) described an analytic method that is 
about to be implemented in a commercial product, but has 
as drawback sensitivity to heterogeneities. Kanawati et al. 
(2015) described a variance reduction method (pgTLE) that 
accelerates the PG estimation by precomputing PG 
production probabilities as a function of energy and target 
materials, but has as drawback that it only works for 
analytical phantoms. 
Materials/Methods: We present a two-stage method, 
voxellized pgTLE (vpgTLE) that extends pgTLE to voxellized 
volumes. PG production probabilities are precomputed once, 
stored, and reused. In stage one, we simulate the 
interactions between the treatment plan and the patient CT 
with low statistic MC to obtain the spatial and spectral 
distribution of the PGs. As primary particles are propagated 
throughout the patient CT, the PG yields are computed in 
each voxel from the initial database, as function of the 
current energy of the primary, the material in the voxel and 
the step length. The result is a voxellized PG yield image, 
normalized to a single primary. The second stage uses the 
intermediate PG image as a source to generate and 
propagate PGs throughout the rest of the scene geometry, 
e.g. into a detection device, proportional to the number of 
primaries desired. 
Results: We have achieved a global speed-up of around 103 
for a heterogeneous phantom, for a 2% relative uncertainty 
on the PG yield. The method agrees with a reference Monte 
Carlo simulation to within 1% at the level of 2% relative 
uncertainty on the PG. Preliminary work on a full simulation 
of a clinical spot-scanning treatment plan and a patient CT 
image indicates a similar gain factor. Gains per voxel range 
from 102 to 105. 
Conclusion: We presented a generic PG yield estimator, drop-
in usable with any geometry and beam configuration. We 
showed a gain of around three orders of magnitude compared 
to analog MC. With a large number of voxels and materials, 
memory consumption may be a concern and we will discuss 
the consequence and possible trade-offs. The method will be 
available in the next release of Gate. 
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Metabolic Tumour Volume (MTV) is defined as the volume on 
FDG-PET/CT with increased FDG uptake. MTV has been shown 
to be of superior prognostic value compared to SUVmax in 
NSCLC. This study aims to explore the spatial overlap 
between CT-derived Gross Tumour Volume (GTV) and FDG-
PET/CT derived MTV. The second aim was to investigate the 
impact of this overlap on progression-free survival (PFS) and 
overall survival (OS). 
This was a single institution review performed in South 
Western Sydney, Australia. Inclusion criteria included proven 
NSCLC, stage I-III disease, radical radiotherapy and received 
PET imaging no more than 105 days before Tx. All FDG-PET 
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scans were from the mid-brain to proximal femora using a 
dedicated Philips Gemini GXL PET/CT scanner. If a 
patient underwent more than one FDG-PET/CT scan, the 
most recent available study was used for analysis. All FDG-
PET/CT data was reviewed on OsiriX (version 5.1.2). All 
metabolically active disease regions on FDG-PET/CT studies 
were manually contoured by consensus between a nuclear 
medicine physician  and a radiation oncologist. 
Spatial overlap between MTV and GTV was measured using 
the Dice similarity coefficient (DSC) which was calculated in 
Matlab with CERR and in house scripts. The value of a DSC 
ranges from 0, indicating no spatial overlap between two 
volumes in spaces, to 1, indicating complete spatial overlap. 
Other geometric descriptors were also calculated including 
volume, centre of mass and dimension. Univariate Cox 
regression was used to determine whether DSC was 
associated with OS and PFS.  
Forty three patients were included in the study with a 
median age of 69 years (51-91). Median follow-up was 1.8 
years (0.6-6.1) with 29 patiens experiencing relapse, there 
were 13 patients alive at the time of analysis and 30 
deceased. The median value for the treated GTV volumes 
and the DSC was 77.4 (3.7-387.3) and 0.63 (0.18-0.86) 
respectively. The DSC was not found to be associated with 
PFS (p=0.85) or OS (p=0.70).  
 
 
Figure 2 Boxplot displaying values of Dice similarity 
coefficient for MTV and GTV 
 
Results in a small cohort show a moderate overlap between 
GTV and MTV, as represented by the DSC and that there is 
limited correlation between this and OS or PFS. Further 
investigation in a larger sample with modern treatment 
techniques (i.e. IMRT, VMAT and SBRT) will aid in clarifying 
the relationship, if any, between known clinical prognostic 
factors, novel metabolic parameters and the end-points of 
progression-free survival and overall survival. 
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Purpose: Biological effects of proton beam irradiation, 
despite their wide clinical use, are not well understood. In 
recent years some differences in DNA repair 
mechanisms[1][2], angiogenesis and metastatic potential 
between proton beam and X-ray radiation were 
described[3,4]. 
Materials/methods: Mel270 human uveal melanoma cells, 
derived from primary tumor, were irradiated with 1 – 5 Gy of 
X ray (300 kVp Phillips, 1Gy/min) or proton beam (58 MeV) 
from Proteus C-235 cyclotron. Cells were analysed for 
survival using both rate of proliferation and clonogenic assay. 
DNA damage was evaluated after 4 and 8 hours using 
immunofluorescence staining of γ-H2AX, 53BP1 (for double 
strand breaks) and XRCC1 (for single strand breaks) and 
detection with confocal microscopy. 
Results: Mel270 proliferation was slightly inhibited after 1 
Gy, and strongly inhibited after 5 Gy. RBE value for Mel270 
cells was determined. Staining of proteins showing DNA 
damage present several distinctive features.The foci of γ-
H2AX were bigger than the others. Two kinds of foci could be 
distinguished:1) with high colocalization preference, below 
1μm between foci; 2) random distribution, above 1μm 
between foci. The number of SSBs foci is higher at 4 than at 
8 h after irradiation.  
Conclusions: Low doses of proton beam irradiation and X rays 
damage DNA affecting the formation of foci indicating single 
and double strand breaks. The number of SSBs decreases with 
time. 
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Two charged particle accelerators are currently in operation 
at the Heavy Ion Laboratory, University of Warsaw (HIL UW): 
a K=160 isochronous cyclotron accelerating gaseous ions from 
He to Ar to energies from 2 to 10 MeV/nucleon and a high 
current medical p/d cyclotron, accelerating protons to an 
energy of 16 MeV and deuterons to an energy of 8 MeV. The 
alpha particle beam from the isochronous cyclotron and 
protons and deuterons from the medical cyclotron are 
currently used to produce research quantities of therapeutic 
and diagnostic radioisotopes. Occasionally, the C30 proton 
cyclotron at Świerk at National Centre for Nuclear Research 
is also employed. 
The present research program includes the production of the 
Targeted Alpha Therapy isotope 211At, the prospective PET 
radioisotopes 43Sc,44Sc and 44mSc and the positron generator 
